

Tosoh AIA & Tosoh AIA	4	170.2	S 137.46	10.92	120.5	S 99.12	7.13	-	-	-	9
Initial Grouping by Reagent											
Siemens Advia/Centaur/CP/XP	3	33.9 - 75.6	S 54.75	6.94	26.7 - 60.3	S 43.5	5.61	-	-	-	6
Tosoh AIA	4	88.6 - 183.4	S 135.96	15.8	71.5 - 127.6	S 99.55	9.34	-	-	-	8
Initial Grouping by Sensitivity or Principle											
Luminometric	5	33.9 - 75.6	S 54.75	6.94	26.7 - 60.3	S 43.5	5.61	-	-	-	6
Immunofluorometric-not FPIA	6	88.6 - 183.4	S 135.96	15.8	71.5 - 127.6	S 99.55	9.34	-	-	-	8
Total Population											
Whole Population	7	0 - 224.8	S 98.21	42.2	0 - 160.6	S 73.32	29.08	-	-	-	15

CA-125

Initial Grouping by Reagent and Instrument											
Beckman Coulter Access & Beckman Coulter Access	1	55 - 102	P 78.5	3.1	39 - 73	P 55.8	3.5	-	-	-	8
Roche Elecsys & Roche e/c, 1XX, X000, Elec series	2	111 - 206	P 158.4	7.5	78 - 145	P 111.9	5.1	-	-	-	9
Roche Elecsys & Roche e411/e601/E170/E2010	3	113 - 210	P 161.2	8.0	79 - 147	P 113.0	5.8	-	-	-	5
Siemens Immulite & Siemens Immulite 2000	4	77 - 142	P 109.5	5.0	54 - 101	P 77.5	1.8	-	-	-	4
Initial Grouping by Reagent											
Abbott Aeroset/Architect	5	107 - 199	P 153.0	37.5	77 - 143	P 109.8	27.0	-	-	-	4
Beckman Coulter Access	6	55 - 103	P 79.2	3.5	40 - 75	P 57.3	4.3	-	-	-	12
Roche Elecsys	7	113 - 209	P 160.8	8.2	79 - 147	P 113.4	6.1	-	-	-	18
Siemens Advia/Centaur/CP/XP	8	77 - 142	P 109.5	3.5	54 - 101	P 77.8	1.8	-	-	-	4
Siemens Immulite	9	80 - 149	P 114.4	7.4	57 - 106	P 81.9	6.9	-	-	-	7
Tosoh AIA	10	199 - 370	P 284.5	10.0	134 - 249	P 191.5	11.2	-	-	-	6
Initial Grouping by Sensitivity or Principle											
Luminometric	11	88 - 163	P 125.5	36.2	62 - 116	P 89.1	25.5	-	-	-	47
Immunofluorometric-not FPIA	12	199 - 370	P 284.5	10.0	134 - 249	P 191.5	11.2	-	-	-	6
Total Population											
Whole Population	13	100 - 187	P 143.5	60.9	70 - 131	P 100.7	40.5	-	-	-	53

Carcinoembryonic Antigen (CEA)

Initial Grouping by Reagent and Instrument											
Abbott Aeroset/Architect & Abbott Architect c, ci, i	1	26.8 - 49.8	P 38.34	3.24	18.5 - 34.4	P 26.44	1.69	-	-	-	5
Beckman Coulter Access & Beckman Coulter Access	2	25.3 - 46.9	P 36.08	3.31	17.0 - 31.6	P 24.27	2.44	-	-	-	11
Beckman Coulter Access & Beckman Coulter DxI	3	24.7 - 45.8	P 35.22	1.97	16.8 - 31.2	P 24.02	1.35	-	-	-	5
Roche Elecsys & Roche e/c, 1XX, X000, Elec series	4	20.1 - 37.4	P 28.75	1.61	13.9 - 25.7	P 19.79	1.14	-	-	-	11
Roche Elecsys & Roche e411/e601/E170/E2010	5	20.7 - 38.4	P 29.52	0.78	14.0 - 26.0	P 20.02	0.51	-	-	-	5
Siemens Advia/Centaur/CP/XP & Siemens Centaur/Centaur CP	6	30.0 - 55.7	P 42.82	1.7	19.3 - 35.9	P 27.59	1.98	-	-	-	7
Siemens Immulite & Siemens Immulite 2000	7	32.3 - 60.0	P 46.13	2.41	21.9 - 40.7	P 31.3	1.78	-	-	-	7
Tosoh AIA & Tosoh AIA	8	38.0 - 70.5	P 54.26	2.82	26.6 - 49.4	P 38.02	1.08	-	-	-	5
Tosoh AIA & Tosoh AIA ST	9	37.0 - 68.6	P 52.8	0.87	25.7 - 47.7	P 36.73	0.5	-	-	-	4
Initial Grouping by Reagent											
Abbott Aeroset/Architect	10	26.8 - 49.8	P 38.34	3.24	18.5 - 34.4	P 26.44	1.69	-	-	-	5
Beckman Coulter Access	11	25.1 - 46.6	P 35.81	2.98	16.9 - 31.4	P 24.19	2.17	-	-	-	16
Roche Elecsys	12	20.3 - 37.7	P 28.99	1.42	13.9 - 25.9	P 19.93	1.03	-	-	-	20
Siemens Advia/Centaur/CP/XP	13	30.0 - 55.7	P 42.82	1.7	19.3 - 35.9	P 27.59	1.98	-	-	-	7
Siemens Immulite	14	32.7 - 60.8	P 46.78	2.28	22.3 - 41.4	P 31.83	1.95	-	-	-	11
Tosoh AIA	15	37.5 - 69.7	P 53.61	2.3	26.2 - 48.7	P 37.44	1.08	-	-	-	9
Initial Grouping by Sensitivity or Principle											
Lower recovery methods	16	22.9 - 42.5	P 32.7	4.41	15.5 - 28.9	P 22.21	3.04	-	-	-	44
Higher recovery methods	17	33.8 - 62.8	P 48.29	4.79	22.8 - 42.4	P 32.63	4.25	-	-	-	27
Total Population											
Whole Population	18	27.0 - 50.2	P 38.63	8.87	18.3 - 34.0	P 26.14	6.17	-	-	-	71

Prostate Specific Ag, Free

Initial Grouping by Reagent and Instrument											
Abbott AxSYM/Aeroset/Archit & Abbott Architect c, ci, i	1	5.3 - 9.8	P 7.57	0.28	3.5 - 6.5	P 4.97	0.31	-	-	-	4
Beckman Coulter Access & Beckman Coulter Access	2	7.2 - 13.4	P 10.34	0.65	5.0 - 9.2	P 7.07	0.39	-	-	-	9
Beckman Coulter Access & Beckman Coulter DxI	3	7.8 - 14.6	P 11.2	0.59	5.3 - 9.8	P 7.5	0.41	-	-	-	4

Roche Elecsys & Roche e/c, 1XX, X000, Elec series	4	5.4 - 10.0	P 7.68	0.2	3.6 - 6.7	P 5.13	0.16	-	-	4
Roche Elecsys & Roche e411/e601/E170/E2010	5	5.4 - 9.9	P 7.65	0.27	3.6 - 6.6	P 5.1	0.19	-	-	4
Initial Grouping by Reagent										
Abbott Axsym/Aeroset/Archit	6	5.3 - 9.8	P 7.57	0.28	3.5 - 6.5	P 4.97	0.31	-	-	4
Beckman Coulter Access	7	7.4 - 13.7	P 10.57	0.73	5.0 - 9.3	P 7.17	0.44	-	-	14
Roche Elecsys	8	5.3 - 9.9	P 7.64	0.23	3.6 - 6.6	P 5.1	0.17	-	-	9
Initial Grouping by Sensitivity or Principle										
Moderate recovery methods	9	6.5 - 12.0	P 9.25	1.69	4.4 - 8.1	P 6.23	1.18	-	-	24
High recovery methods	10	5.3 - 9.9	P 7.64	0.23	3.6 - 6.6	P 5.1	0.17	-	-	9
Total Population										
Whole Population	11	6.2 - 11.5	P 8.81	1.61	4.1 - 7.7	P 5.92	1.13	-	-	33

Prostatic Acid Phosphatase (PAP)

Total Population										
Whole Population	1	0 - 1.6	C 0.4	0.0	0 - 1.6	C 0.4	0.0	-	-	1

Thyroglobulin

Initial Grouping by Reagent										
Beckman Coulter Access	1	21.7 - 88.9	S 55.32	11.2	17.4 - 59.9	S 38.66	7.1	-	-	5
Initial Grouping by Sensitivity or Principle										
Luminometric	2	23.0 - 92.6	S 57.77	11.6	17.8 - 63.0	S 40.38	7.54	-	-	6
Total Population										
Whole Population	3	0 - 109.6	S 51.13	19.48	0 - 73.9	S 36.1	12.6	-	-	7